ANDA 202546, held by Beximco Pharms USA. Ribavirin.
As of Nov 14, 2026, ANDA 202546 (Ribavirin), held by Beximco Pharms USA, was first approved by FDA on Aug 12, 2014, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 12, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
